LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Search

Pacific Biosciences of California Inc

Closed

SectorHealthcare

1.33 5.56

Overview

Share price change

24h

Current

Min

1.32

Max

1.33

Key metrics

By Trading Economics

Income

-2.4M

-40M

Sales

6.2M

45M

Profit margin

-90.427

Employees

485

EBITDA

-6M

-38M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+87.4% upside

Dividends

By Dow Jones

Next Earnings

7 maj 2026

Market Stats

By TradingEconomics

Market Cap

-136M

420M

Previous open

-4.23

Previous close

1.33

Technical Score

By Trading Central

Confidence

Bullish Evidence

Pacific Biosciences of California Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 mar 2026, 19:08 UTC

Major News Events

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

13 mar 2026, 18:48 UTC

Earnings
Major Market Movers

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

13 mar 2026, 17:10 UTC

Major News Events

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

13 mar 2026, 17:10 UTC

Major News Events

Week Ahead for FX, Bonds: Central Bank Decisions -2-

13 mar 2026, 16:47 UTC

Major News Events

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

14 mar 2026, 02:03 UTC

Earnings

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14 mar 2026, 01:32 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14 mar 2026, 00:29 UTC

Acquisitions, Mergers, Takeovers

13D Filings -- Barrons.com

13 mar 2026, 22:27 UTC

Market Talk
Major News Events

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13 mar 2026, 22:13 UTC

Market Talk
Major News Events

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13 mar 2026, 22:04 UTC

Market Talk
Major News Events

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13 mar 2026, 22:00 UTC

Acquisitions, Mergers, Takeovers

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

13 mar 2026, 20:50 UTC

Market Talk
Major News Events

Financial Services Roundup: Market Talk

13 mar 2026, 20:02 UTC

Market Talk

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13 mar 2026, 19:50 UTC

Market Talk
Major News Events

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13 mar 2026, 19:35 UTC

Major News Events

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

13 mar 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

13 mar 2026, 18:49 UTC

Major News Events

The Iran War Could Upend AI. Here's How. -- Barrons.com

13 mar 2026, 18:24 UTC

Major News Events

Impact of Middle East Conflict on TotalEnergies Activities

13 mar 2026, 18:00 UTC

Major News Events

Is War Good For the Economy? -- WSJ

13 mar 2026, 17:23 UTC

Market Talk

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

13 mar 2026, 16:46 UTC

Market Talk
Major News Events

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

13 mar 2026, 16:38 UTC

Major News Events

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

13 mar 2026, 16:34 UTC

Acquisitions, Mergers, Takeovers

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

13 mar 2026, 16:33 UTC

Acquisitions, Mergers, Takeovers

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

13 mar 2026, 16:32 UTC

Acquisitions, Mergers, Takeovers

EQT Completes Exit From Galderma

13 mar 2026, 16:20 UTC

Market Talk
Major News Events

Financial Services Roundup: Market Talk

13 mar 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

13 mar 2026, 16:15 UTC

Major News Events

Why Exxon and Energy Stocks Finally Started to Rise This Week as the Iran War Escalated -- Barrons.com

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

87.4% upside

12 Months Forecast

Average 2.38 USD  87.4%

High 3 USD

Low 1.5 USD

Based on 5 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

2

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

1.13 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat